ACRIA Studies in Progress
People 18 and older who have persistent diarrhea will first take crofelemer or placebo tablets for 6 weeks. Then everyone will take crofelemer for 5 months.
People with insulin resistance will take Avandia (rosiglitazone), or Serostim (growth hormone), or both for 6 months to see how they affect glucose, insulin levels and body shape.
People aged 18-60 who have taken an NRTI, NNRTI and PI, and have developed resistance or stopped the drugs for other reasons, will take KP-1461 (a new type of NRTI) with no other ARVs for four months.
People 18 and older (half white and half non-white, half men and half women) who have taken an NRTI, NNRTI and PI (not Aptivus) and who have resistance to at least two PIs, will take a standard dose of Aptivus or receive therapeutic drug monitoring to find the best dose for them.
People who have developed resistance to Reyataz will come in for one day of blood tests to study the I50L mutation.
People aged 18 and over who have resistance to at least three classes of HIV meds will take either maraviroc (Selzentry) or INCB 9471, a new once-per-day CCR5 inhibitor.
In addition to oral HIV meds, people will be given IV infusions of placebo or one of four doses of ibalizumab, a monoclonal antibody designed to block HIV entry.
For more information on these trials, contact us at 212-924-3934 ext. 121.
People 18 and older who have limited treatment options and resistance to approved NNRTIs, and who have taken an NRTI, NNRTI and at least two PIs, may qualify for early access to this experimental NNRTI.
People with HIV who have peripheral neuropathy will use either Transacin (capsaicin) patches or very low-dose patches for 30 or 60 minutes a day for 3 months. Participants must be 18 or older and have had pain in both feet for at least 2 months.
People aged 18-65 who have excess abdominal fat will take either TH9507 (an investigational growth hormone releasing factor), or a placebo for 26 weeks. The two groups will then switch for 26 more weeks.
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.